Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
MLTX
MoonLake Immunotherapeuti
$8.43
Login to see MoonLake Immunotherapeuti (MLTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Technical Indicators
MACD above signal line
Chart
$57 (-85.21%)
$50.86 (-83.43%)
$36.76 (-77.07%)
$48.94 (-82.77%)
MLTX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
MLTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
MLTX Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MLTX Street view is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayMLTX Earnings
The TTM reflects 12-month period, providing review of MLTX financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
MRK
89.19
-0.36%
SNY
50.90
+1.52%
LLY
839.87
+2.44%
ANAB
30.94
-1.28%
ABBV
233.87
-1.12%
What is MLTX current stock price?
What are MLTX stock strengths?
What risks are associated with MLTX stock?
When is MLTX next earnings report?
What is MLTX market cap and volume?
What is MLTX's current Stock IQ?
Should I buy MLTX stock right now?
Is MLTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for MLTX?
What does a 'Strong Sell' rating mean for MLTX?
What factors influence MLTX's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
MLTX
MoonLake Immunotherapeuti
Current Price
$8.43
Stock Insights
Strengths
Upgraded on attractively valued
Technical Indicators
MACD above signal line
Linked to MLTX
MRK
89.19
-0.36%
SNY
50.90
+1.52%
LLY
839.87
+2.44%
ANAB
30.94
-1.28%
ABBV
233.87
-1.12%
Login to unlock MoonLake Immunotherapeuti (MLTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$57 (-85.21%)
$50.86 (-83.43%)
$36.76 (-77.07%)
$48.94 (-82.77%)
MLTX Analysts Opinion
MLTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
MLTX Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MLTX Street view is unimpressive and have negative views on the near-term outlook
MLTX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Average key support and resistance price levels.
Login to displayMLTX Earnings
The TTM data reflects the most recent 12-month period, providing overview of MLTX financial performance.
MLTX Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
MLTX Latest Analysis
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX. announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (MoonLake or the Company) (NASDAQ: ) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. MoonLake'.s communications to
Wed Oct 1, 2025
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman. SAN FRANCISCO Sept. 30 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether MoonLake may have misled investors about sonelokimab'.s trial design and efficacy.The firm urges investors in Moon
Tue Sep 30, 2025
Needham Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation. Fintel reports that on September 30 2025 Needham maintained coverage of MoonLake Immunotherapeutics (NasdaqCM:MLTX) with a Buy recommendation. Analyst Price Forecast Suggests 1189.22% Upside
Tue Sep 30, 2025
MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment. MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its highly anticipated skin disease drug.The post MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment appeared first on Investor'.s Business Daily.
Mon Sep 29, 2025
MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment. MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its highly anticipated skin disease drug.The post MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment appeared first on Investor'.s Business Daily.
Mon Sep 29, 2025
Inventiva MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Mondays Pre-Market Session. United States stock futures were higher this morning with the Dow futures gaining more than 100 points on Monday.Shares of ) fell sharply in today'.s pre-market trading following H1 results.Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate of loss of 41 cents per share. The company reported quarterly sales of $5.050 million which missed the analyst co
Mon Sep 29, 2025
MoonLake plunges after mixed results from skin disease trial.
Mon Sep 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MLTX Stock trends
MLTX Stock performance
MLTX Stock analysis
MLTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings